Quantcast

Latest HPV Stories

2014-09-22 08:28:19

Expansion Comes After Successful Phase II Trial for Cervical Dysplasia PLYMOUTH MEETING, Pa., Sept. 22, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today it has initiated a phase I clinical trial in patients with aerodigestive cancers. The trial will evaluate the safety, tolerability, and immunogenicity of INO-3106. This immunotherapy targets human papillomavirus type 6 (HPV-6), which causes most aerodigestive cancers. Aerodigestive cancers affect the...

2014-08-25 08:27:55

SEATTLE, Aug. 25, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that results from two independent clinical studies were presented at the 29th International Papillomavirus (IPV) Conference. Results from both pilot studies consistently demonstrated that the Company's urine-based assay for the detection of high-risk HPV had high sensitivity (greater than 90%) for identifying women with high grade cervical...

2014-08-22 12:25:19

LA JOLLA, Cali., Aug. 22, 2014 /PRNewswire/ -- Research presented at the 29(th) Annual International Papillomavirus Conference shows that a therapy being developed by Hera Therapeutics Inc. combats three types of human papillomavirus, including the two that cause 70 percent of all cervical cancer. When tested in several cultured human cell models, HTI-1968 blocked the replication of HPV-16, HPV-18 and HPV-11 cells, according to Louise T. Chow, Ph.D. and Thomas Broker, Ph.D., who...

2014-08-20 08:27:55

SAN DIEGO, Aug. 20, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that results from two clinical studies will be presented at the 29th International Papillomavirus (IPV) conference for the Company's urine-based diagnostic test for the detection of high risk strains of Human Papillomavirus (HPV). The IPV conference is scheduled to take place in Seattle from August 21(st) to 25(th). Additionally, a new U.S. patent...

2014-08-05 08:34:12

HPV mRNA positive and Ct/Ng negative controls reduce repeat molecular testing MILFORD, Mass., Aug. 5, 2014 /PRNewswire/ -- SeraCare Life Sciences, a provider of high-quality biological materials that help optimize diagnostic performance, reliability and repeatability across the IVD lifecycle, today announced the launch of two new ACCURUN(®) products - the first HPV mRNA positive and Ct/Ng negative controls for the company. http://photos.prnewswire.com/prnvar/20140804/132910...

2014-08-01 10:49:36

Landes Bioscience A long-term follow-up study (HPV-023; NCT00518336) shows the sustained efficacy, immunogenicity and safety of GlaxoSmithKline's human papilloma virus (HPV) vaccine Cervarix. Women vaccinated with the HPV-16/18 AS04-adjuvanted vaccine were followed for more than nine years, and vaccine efficacy (VE) against incident infection was 100%. This is the longest follow-up report for a licensed HPV vaccine. Visit https://www.landesbioscience.com/journals/vaccines/article/29532/...

2014-08-01 10:35:50

Johns Hopkins Medicine Physicians at Johns Hopkins have developed blood and saliva tests that help accurately predict recurrences of HPV-linked oral cancers in a substantial number of patients. The tests screen for DNA fragments of the human papillomavirus (HPV) shed from cancer cells lingering in the mouth or other parts of the body. A description of the development is published in the July 31 issue of JAMA Otolaryngology – Head & Neck Surgery. "There is a window of opportunity...

2014-07-29 16:26:30

VENLO, the Netherlands, July 29, 2014 /PRNewswire/ -- - Achieved Q2 2014 targets: Adjusted net sales of $331.2 million (+4% CER); adjusted operating income of $81.2 million and 25% operating margin; adjusted EPS of $0.26 CER - H1 2014 adjusted net sales rise approximately 8% CER excluding U.S. HPV tests, in line with full-year 2014 goal; H1 2014 free cash flow rises 28% to $77 million...

2014-07-23 08:32:38

Treatment with VGX-3100 induces regression of precancerous cervical disease and clears HPV infection with robust T cell responses PLYMOUTH MEETING, Pa., July 23, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced successful results from its randomized, double-blind, placebo-controlled phase II trial of VGX-3100 in women with biopsy-proven cervical intraepithelial neoplasia 2/3 (CIN2/3) associated with human papillomavirus (HPV) types 16 or 18. Treatment...

2014-06-23 04:20:45

Inovio's Immunotherapy will Treat Women with Inoperable HPV-caused Cancer BLUE BELL, Pa., June 23, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced it has initiated a phase I/IIa clinical trial to evaluate safety, immunogenicity, clinical responses and disease-free survival of its DNA immunotherapy product, INO-3112, in treating human papillomavirus (HPV)-associated cervical cancer. INO-3112 is a combination of Inovio's lead active immunotherapy...


Latest HPV Reference Libraries

0_d7e189bb6feb0f5663af7d072b6f51c6
2011-02-17 14:56:32

A human papillomavirus (HPV), a member of the papillomavirus family, is capable of infecting humans. HPVs establish productive infections in the skin or mucous membranes. Most of the 200 known types cause no symptoms in most people. Some types can cause warts, while others can lead to cancer. There are more than 30 to 40 types of HPV that are typically transmitted through sexual contact and infect the anogenital region. High risk HPV, can lead to cancer, in fact HPV infection is a cause of...

More Articles (1 articles) »
Word of the Day
conjunto
  • A style of popular dance music originating along the border between Texas and Mexico, characterized by the use of accordion, drums, and 12-string bass guitar and traditionally based on polka, waltz, and bolero rhythms.
The word 'conjunto' comes through Spanish, from Latin coniūnctus, past participle of coniungere, to join together; see conjoin